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Penetrance Estimates for Incidental Genomic Findings
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Division of Health Sciences and Technology, Harvard-MIT
Department of Biomedical Informatics, Harvard Medical School

INTRODUCTION

(Genetic Testing and Relevant Datasets)
Genetic testing: a difference from the reference
genome (variant) may indicate disease.
Incidental finding: variant in gene unrelated to
diagnostic indication that prompted sequencing.
-Due to multiple testing and low priors, these
typically have high rates of false positives,
so we normally don’t report them.
ACMG (American College of Medical Genetics
& Genomics): recommends an exception for 56
genes thought to be more indicative of disease.

1000 Genomes Project: contains whole-genome
sequence data for 2,504 healthy adults from
diverse ethnic populations.
ExAC: aggregates population-level data from
60,706 diverse human whole-genome sequences.
ClinVar: central repository of interpretations for
genetic variants (benign vs. pathogenic).

OBJECTIVES
1. Develop an ETL workflow for extraction,
transformation, and loading of genomic and
interpretation data from relevant sources.
2. Evaluate variant distribution across a
healthy, diverse cohort (1000 Genomes).
3. Estimate plausible penetrance ranges
for the ACMG recommendations.

CONCLUSIONS

PENETRANCE MODEL
𝑃 𝐷 ∗ 𝑃(𝑉|𝐷)
𝑝𝑟𝑒𝑣𝑎𝑙𝑒𝑛𝑐𝑒 𝑎𝑙𝑙𝑒𝑙𝑖𝑐 ℎ𝑒𝑡𝑒𝑟𝑜𝑔𝑒𝑛𝑒𝑖𝑡𝑦
𝑃𝑒𝑛𝑒𝑡𝑟𝑎𝑛𝑐𝑒 = 𝑃 𝐷 𝑉 =
=
𝑃 𝑉
(𝑎𝑙𝑙𝑒𝑙𝑒 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦)
where D = disease, V = any variant

Penetrance:
Prevalence:
Allelic Heterogeneity:
Allele Frequency:

Probability of developing disease, given a positive genetic test result.
Proportion of general population with disease.
Proportion of diseased population with a pathogenic variant.
Proportion of general population with a pathogenic variant.

METHODS & WORKFLOW
ETL for Datasets
Pipeline + UI using R/Shiny/Markdown
1. Extract: query UCSC Genome Browser for
gene regions and retrieve corresponding VCF
files from 1000 Genomes. Download ExAC
manually from gene-level searches.
2. Transform: separate variants with multiple
alternates; convert genotypes to allele counts,
collect missense variants.
3. Load: Stage and merge final data objects.

https://github.com/jamesdiao/2016-paper-ACMG-penetrance

KEY FIGURES
Heatmap + Barplot: Penetrance Estimates are Low and Variable between Ancestral Groups

1. High counts: 40-80% of individuals have
an incidental finding under ACMG guidelines,
far higher than empirical disease prevalences.
2. Clustered distribution: by ethnicity –
AFR (African) have the most findings,
EAS (East Asian) have the fewest.
3. High sensitivity: findings dominated
by a few high-frequency variants.
4. Very low penetrance estimates:
Out of the 30 diseases (22 with data):
(a) 20 have max theoretical penetrance < 50%
(b) 12 have max theoretical penetrance < 5%
5. High uncertainty around parameters:
translates into very large errors bars.
-This is a preliminary “letter-of-the-law”
evaluation and does not yet demonstrate
real-world effects on patients.

NEXT STEPS
1. Identify questionable variants:
(a) high-frequency (common findings)
(b) highly enriched in 1 ethnic population.
2. Validation with empirical penetrance values
and other sequencing datasets (e.g. gnomAD).
3. Model biases in parameter estimates
(prevalence, pathogenicity, etc.)
4. Confer with clinical collaborators
to determine alternate protocols at Laboratory of
Molecular Medicine and Partners HealthCare.
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